Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Project Grant - PA: Breast Cancer Research

McGill University

$100,000.00

Identifying the molecular and environmental factors involved in promoting escape from breast cancer dormancy.

EF 2022-23

Résumé
Breast cancer remains the second deadliest cancer for Canadian women and its morbidity is largely attributed to relapse in patients from recurrent tumors. Tumors that enter a state of dormancy can eventually reactivate and often confer drug resistance and grow at an accelerated rate, hence persisting as the main hurdle in current treatment. However, the factors that promote cancer recurrence are still poorly understood. We envision that by studying the changes and characterizing the compensatory mechanisms as tumors transition from dormant to recurrent, we will uncover druggable targets that can synergize with current therapies to avert breast cancer recurrence and improve patient outcome.
Programme
Project Grant - PA: Breast Cancer Research
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
483129
Name
Muller William J
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Cancer Progression & Therapeutics
Projecttitle
Identifying the molecular and environmental factors involved in promoting escape from breast cancer dormancy.
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant - PA: Breast Cancer Research
Keyworddelim
Breast Cancer; Breast Cancer Recurrence; Dormancy; Her2; Immune Surveillance; Osteopontin; Stat1
Abstract
Breast cancer remains the second deadliest cancer for Canadian women and its morbidity is largely attributed to relapse in patients from recurrent tumors. Tumors that enter a state of dormancy can eventually reactivate and often confer drug resistance and grow at an accelerated rate, hence persisting as the main hurdle in current treatment. However, the factors that promote cancer recurrence are still poorly understood. We envision that by studying the changes and characterizing the compensatory mechanisms as tumors transition from dormant to recurrent, we will uncover druggable targets that can synergize with current therapies to avert breast cancer recurrence and improve patient outcome.
Competitiondate
202303
Approvedterm2
1 yr 0 mth
Pinamesdelim
Muller, William J
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~